NUVO PHARMACEUTICALS INC.

Miravo Healthcare™ Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

ET

Key Points: 
  • ET
    H.C. Wainwright is a fullservice investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions.
  • H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors.
  • For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com .
  • Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.

Miravo Healthcare™ Announces Receipt of Health Canada Notice of Compliance for the Pediatric Use of Blexten®

Retrieved on: 
Thursday, August 12, 2021
Faes, Health Canada, GMP, NOC, Environment, Population, Dermatology, Goal, Hives, Food, Multimedia, Allergic rhinitis, Pain, Phrase, Disclosure, Tablet, Humanitarian use licenses, Company, Rhinitis, Cetirizine, Allergy, Risk, Itch, View, MRV, Forward-looking statement, TSX, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Neurology, Patient, Adult, Pharmaceutical industry

Upon commercial launch, which is anticipated for Q1 2022, the pediatric formats will be available to patients with a prescription from their healthcare provider.

Key Points: 
  • Upon commercial launch, which is anticipated for Q1 2022, the pediatric formats will be available to patients with a prescription from their healthcare provider.
  • Blexten is a second-generation antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
  • Bilastine, (the active ingredient in Blexten), is approved in Canada and over 100 countries worldwide, including Japan and most European countries.
  • The exclusive license is inclusive of prescription and non-prescription rights for Blexten, as well as adult and pediatric presentations in Canada.

Miravo Healthcare™ Announces Second Quarter 2021 Results

Retrieved on: 
Monday, August 9, 2021
Amortizing loan, SK Group, Conversation, Production, CEO, Board of directors, Republic, Informal economy, MD, CPP Investment Board, Gross v. FBL Financial Services, Inc., Diclofenac, Financial statement, EBITDA, MRV, TSX, License, Conference, Prescription, IFRS, Prospectus, US, DAC, Nature, Service, Board, Company, Health insurance, Animal, Pharmaceutical industry, Credit, Music

ET

Key Points: 
  • ET
    MISSISSAUGA, ON, Aug. 9, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and six months ended June 30, 2021.
  • Adjusted EBITDA(1) was $7.4 million, a decrease of 3% compared to $7.6 million for the three months ended June 30, 2020.
  • As at June 30, 2021, cash and cash equivalents were $27.3 million.
  • In July 2021, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare (Miravo Ireland) entered into an exclusive license and supply agreement with SK Chemicals Co., Ltd. (SK Chemicals) for the exclusive right to commercialize Suvexxin the Republic of South Korea.

Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea

Retrieved on: 
Thursday, July 29, 2021
Companies, Chaebol, SK Group, Economy of South Korea, SK

SK Chemicals is headquartered in Seongnam, South Korea and is part of the SK Group, a major South Korean conglomerate that generated over US$105 billion in revenue in 2020.

Key Points: 
  • SK Chemicals is headquartered in Seongnam, South Korea and is part of the SK Group, a major South Korean conglomerate that generated over US$105 billion in revenue in 2020.
  • "This agreement with SK Chemicalsprovides Suvexx with access to the dynamic and growing acute migraine market in South Korea," said Jesse Ledger, Miravo's President & CEO.
  • "SK Chemicals is a strong partner for Suvexx in South Korea with their complementary CNS product portfolio, and we are pleased to add them to our growing roster of Suvexx partners."
  • The License Agreement grants SK Chemicals the exclusive rights to commercialize Suvexx in the Territory.

Miravo Healthcare™ Announces Second Quarter 2021 Results Release Date and Conference Call Details

Retrieved on: 
Monday, July 26, 2021
Companies, General Electric, RCA, Schenectady, New York, Thomas Edison, Economy of the United States, Industry economics)

MISSISSAUGA, ON, July 26, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2021 financial results before markets open on Monday, August 9, 2021.

Key Points: 
  • MISSISSAUGA, ON, July 26, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2021 financial results before markets open on Monday, August 9, 2021.
  • The Company will subsequently hold a conference call the same day, Monday, August 9, 2021 at 11:00 a.m.
  • ET, hosted by Jesse Ledger, Miravo's President & Chief Executive Officer and other senior management.
  • Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.

Miravo Healthcare™ to Present at Access to Giving Virtual Investor Conference

Retrieved on: 
Thursday, July 8, 2021
Finance, Money, Economy, One Times One, Financial literacy, Investor

Access to Givingis the first-of-its-kind virtual investor conference and will be held July 13th 15th, 2021.

Key Points: 
  • Access to Givingis the first-of-its-kind virtual investor conference and will be held July 13th 15th, 2021.
  • Companies will have the opportunity to tell their story and conduct 1x1 meetings with qualified investors for charity.
  • 100% of monies raised through donations for 1x1 meetings will be given to causes that are focused on financial literacy and financial education.
  • GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.For additional information, please visit www.miravohealthcare.com .

Miravo Healthcare™ to Present at Summer Solstice - Best Ideas from the Buy Side

Retrieved on: 
Thursday, May 27, 2021
Investment, Stock market, Microcap stock, Rodeo, Institutional Investor

The MicroCap Rodeo is back with its third "Best Ideas Bowl."

Key Points: 
  • The MicroCap Rodeo is back with its third "Best Ideas Bowl."
  • This conference is a virtual conference that brings you the top 35 best ideas from the buy side.
  • Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas.
  • Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.

Miravo Healthcare™ Announces Appointment of Mary Ritchie to its Board of Directors

Retrieved on: 
Wednesday, May 19, 2021
Articles, Committees, Corporate law, Business, Economy of Toronto, Toronto Stock Exchange, Audit committee, Board of directors, Ritchie

Ms. Ritchie has over 30 years of experience in both the public, private and not-for-profit sectors and is a Fellow of CPA Alberta.

Key Points: 
  • Ms. Ritchie has over 30 years of experience in both the public, private and not-for-profit sectors and is a Fellow of CPA Alberta.
  • She is a member of the board of directors and audit committees of Alaris Royalty Corp. (TSX), EnWave Corporation (TSXV) and Morien Resources Inc. (TSXV).
  • Ritchie was nominated to join the Board and subsequently appointed during the proceedings of the Miravo Healthcare Annual General Meeting of Shareholders convened on May 17, 2021.\nMiravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.
  • For additional information, please visit www.miravohealthcare.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/miravo-healthcare-announces-appo...\n'

Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

Retrieved on: 
Monday, May 17, 2021
Pharmaceuticals policy, Food safety, Good manufacturing practice, Good practice, Pharmaceutical industry, Life sciences, Articles, Health

The Company's full report of voting results on matters presented at the Meeting can be found at www.sedar.com .\nMiravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.

Key Points: 
  • The Company's full report of voting results on matters presented at the Meeting can be found at www.sedar.com .\nMiravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products.
  • The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology.
  • The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.
  • The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U.

Miravo Healthcare™ Announces First Quarter 2021 Results

Retrieved on: 
Monday, May 17, 2021
Mentholatum, National Register of Historic Places in Buffalo, New York, Naproxen/esomeprazole, OTC Markets Group, Nuvo, Health care, Health, Pharmacology

b'Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET\nMISSISSAUGA, ON, May 17, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2021.

Key Points: 
  • b'Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET\nMISSISSAUGA, ON, May 17, 2021 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2021.
  • For further details on the results, please refer to Miravo\'s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2021, which are available on the Company\'s website ( www.miravohealthcare.com ).
  • Miravo Ireland will earn revenue from The Mentholatum Company pursuant to the License Agreement.
  • During the three months ended March 31, 2021, the Company received a royalty of 10% based on U.S. net sales of Vimovo.